Department of Biochemistry, JSS Medical College, JSS Academy of Higher Education & Research, Mysuru, 570015, India.
Department of Oncology, JSS Medical College, JSS Academy of Higher Education & Research, Mysuru, 570015, India.
Mol Biol Rep. 2024 Sep 9;51(1):972. doi: 10.1007/s11033-024-09892-w.
Multiple myeloma, a complex hematologic malignancy, has devastating consequences for patients, including dramatic bone loss, severe bone pain, and pathological fractures that markedly decrease the quality of life and impact the survival of affected patients. This necessitates a refined understanding of biomarkers for accurate diagnosis and prognosis of such severe malignancy. Therefore, this article comprehensively covers current research, elucidating the diverse spectrum of biomarkers employed in clinical settings. From traditional serum markers to advanced molecular profiling techniques, the review provides a thorough examination of their utility and limitations. Through this scoping review, emphasis is placed on the evolving landscape of personalized medicine, where biomarkers play a pivotal role in tailoring therapeutic strategies. The integration of genomic, proteomic, next generation sequencing and flow cytometric data further enriches the discussion, unravelling the molecular intricacies underlying disease progression. The updated criteria allow for the treatment of people who clearly would benefit from therapy and might live longer if treated before significant organ damage occurs. Navigating through the evolving diagnostic and prognostic paradigms in multiple myeloma, this article equips clinicians and researchers with crucial insights for optimizing patient care and advancing future therapeutic approaches.
多发性骨髓瘤是一种复杂的血液恶性肿瘤，对患者造成严重后果，包括明显的骨质流失、严重的骨痛和病理性骨折，显著降低了生活质量并影响了受影响患者的生存。这就需要深入了解生物标志物，以便对这种严重的恶性肿瘤进行准确的诊断和预后。因此，本文全面涵盖了当前的研究，阐明了在临床环境中使用的各种生物标志物。从传统的血清标志物到先进的分子分析技术，本综述全面考察了它们的实用性和局限性。通过这项范围综述，强调了个性化医学的不断发展，其中生物标志物在制定治疗策略方面发挥着关键作用。基因组学、蛋白质组学、下一代测序和流式细胞术数据的整合进一步丰富了讨论，揭示了疾病进展背后的分子复杂性。更新的标准允许对那些显然受益于治疗且如果在发生严重器官损伤之前进行治疗可能会活得更长的患者进行治疗。本文在多发性骨髓瘤不断发展的诊断和预后模式中进行了探讨，为临床医生和研究人员提供了优化患者治疗和推进未来治疗方法的重要见解。
